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Abstract The renin-angiotensin-aldosterone-system (RAAS)
plays a central role in the pathophysiology of heart failure
and cardiorenal interaction. Drugs interfering in the RAAS
form the pillars in treatment of heart failure and cardiorenal
syndrome. Although RAAS inhibitors improve prognosis,
heart failure–associated morbidity and mortality remain
high, especially in the presence of kidney disease. The
effect of RAAS blockade may be limited due to the loss of
an inhibitory feedback of angiotensin II on renin produc-
tion. The subsequent increase in prorenin and renin may
activate several alternative pathways. These include the
recently discovered (pro-) renin receptor, angiotensin II
escape via chymase and cathepsin, and the formation of
various angiotensin subforms upstream from the blockade,
including angiotensin 1–7, angiotensin III, and angiotensin
IV. Recently, the direct renin inhibitor aliskiren has been
proven effective in reducing plasma renin activity (PRA)
and appears to provide additional (tissue) RAAS blockade
on top of angiotensin-converting enzyme and angiotensin
receptor blockers, underscoring the important role of renin,
even (or more so) under adequate RAAS blockade.
Reducing PRA however occurs at the expense of an
increase plasma renin concentration (PRC). PRC may exert
direct effects independent of PRA through the recently
discovered (pro-) renin receptor. Additional novel
possibilities to interfere in the RAAS, for instance using
vitamin D receptor activation, as well as the increased
knowledge on alternative pathways, have revived the
question on how ideal RAAS-guided therapy should be
implemented. Renin and prorenin are pivotal since these
are at the base of all of these pathways.
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Introduction
The heart and kidney are in close interaction with each
other. In patients with heart disease, concomitant renal
disease is an important prognostic factor, and vice versa,
patients with renal disease often suffer and die from cardiac
diseases. Morbidity and mortality associated with cardio-
renal failure (cardiorenal syndrome) remains very high, and
several ‘‘cardiorenal connectors’’ have been described to
explain why decreased function of one organ leads to
dysfunction of the other [1, 2]. In this cardiorenal con-
nector concept, the renin-angiotensin-aldosterone-system
(RAAS) plays a pivotal role.
The RAAS is a key regulatory system of cardiovascular
(CV), renal, and adrenal function, which maintains body
ﬂuid and electrolyte balance, as well as arterial pressure.
The classical RAAS consists of a circulating endocrine
system in which the principal effector hormone is angio-
tensin (ANG) II. The conversion of angiotensinogen to
ANG I by renin is the ﬁrst and rate-limiting step in the
RAAS. Although activation of this system may be appro-
priate as an initial response to hypoperfusion (as in early
stages of cardiac and renal disease), chronic activation of
the RAAS is a major contributing factor to the pathogenesis
and progression of CV and renal disease. Blockade of the
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(ACEi), angiotensin receptor blockers (ARBs), and aldo-
steronereceptorantagonistsaldosteroneantagonists(ARAs)
has become the cornerstone of treatment in patients at
various stages of heart and kidney disease, from early
disease (hypertension and diabetes mellitus) to advanced
severe end-organ cardiorenal failure (including nephropa-
thy, heart failure, and combined cardiorenal failure).
However, in clinical and experimental studies, the sup-
pression of ANG II and/or aldosterone generation by ACEi
and/or ARBs does not result in persistently decreased ANG
II and aldosterone plasma levels. Through various ‘‘escape’’
mechanisms, ANG II and aldosterone levels may return to
pretreatment levels or even exceed them [3]. One of the
factors that may contribute to the reduced effectiveness of
RAAS blockers is the compensatory increase in renin and
ANG I levels in response to interruption of the negative
feedback activity of ANG II signaling. Although deemed
unharmful for a long time, recent analyses of clinical trials
with RAAS inhibitors suggested that sustained elevations of
renin levels are clearly associated with worse outcome [4,
5]. Moreover, recent evidence suggests that these increases
in renin may have additional, non-RAAS-dependent effects,
since renin has been shown to interact with the recently
discovered (pro-) renin receptor [6].
In this review, we will focus on the role of renin and its
inactive precursor prorenin in the progression of cardiore-
nal disease, with an emphasis on direct renin inhibition and
effects beyond the classical RAAS such activation of the
(pro-) renin receptor ((P)RR) Fig. 1.
Prorenin and renin chemistry, physiology,
and pathophysiology
Structure and synthesis
Renin is an enzyme that belongs to a family of aspartic
proteases that also includes pepsin, cathepsin, and chy-
mosin [7]. It consists of 350 amino acids that form 2
homologous lobes with an active side located in the cleft
between them. The active site has 2 aspartic acid residues
and, in contrast to the other aspartic proteases, is highly
speciﬁc for its substrate angiotensinogen due to a distinct
subpocket (S3sp). Prorenin is the inactive proenzyme form
of renin characterized by an additional 43-amino acid
prosegment covering the enzymatic cleft [8, 9].
The ﬁrst step in renin synthesis is the production of
preprorenin in the juxtaglomerular cells. In the cisterns of
the endoplasmic reticulum, the signal peptide is cleaved off
and prorenin is formed and directed to the cis-Golgi cis-
terns [10]. Prorenin can be either excreted immediately or
converted to renin, by cleaving off the prosegment, and
stored in dense core vesicles [11, 12]. The amount of
prorenin that is cleaved into renin is relatively low, being
around 25% [13]. In addition several extrarenal sites have
been identiﬁed that produce prorenin, whereas renin pro-
duction is mostly limited to the kidney. Therefore, circu-
lating prorenin levels are 5- to 10-fold higher than those of
renin [14]. The prorenin/renin ratio is, however, not a
constant. In diabetes mellitus for instance, the ratio is
markedly increased.
Regulation of (pro-) renin release
Given the important homeostatic actions of the RAAS on
the cardiovascular system, it is not surprising that the
synthesis and secretion of (pro-) renin are tightly con-
trolled. Prorenin release is continuous and depends on the
level of gene activation, transcription efﬁciency in the
individual cell and the total number of (pro-) renin-pro-
ducing cells. This is unaltered by acute stimuli, but may be
inﬂuenced by chronic stimuli. Interestingly, chronic stimuli
also cause more prorenin to be converted to renin,
decreasing the prorenin/renin ratio [15]. The most striking
exception to this rule is diabetes with end-organ damage, in
which prorenin levels are increased out of proportion to
Fig. 1 Renin receptor pathway
192 Heart Fail Rev (2012) 17:191–201
123renin [16, 17]. This increase is not apparent in patients with
uncomplicated diabetes. It appears that this may be due to
decreased clearance of prorenin from the circulation and/or
increased production from extrarenal sources [18]; how-
ever, the exact mechanisms remain to be elucidated. The
increase in prorenin levels in diabetes with end-organ
damage suggests that not only renin but also prorenin
levels are important markers of (tissue) RAAS activation.
In contrast to prorenin, renin release is not continuous.
In a rat afferent arteriole, the spontaneous discharge rate of
a single renin containing granule was observed on average
once every 5 min [19]. Unlike prorenin, renin release can
be increased rapidly in response to acute stimuli, by
secretion of stored renin from the dense core vesicles [15].
The rate of renin excretion can be increased through sev-
eral stimuli. The four main stimuli for renin release are: (1)
decreased stretch in the baroreceptors of the afferent arte-
riole, (2) decreased sodium chloride delivery to the macula
densa, (3) activation of renal sympathetic nerves and
stimulation of b-adrenergic receptors, and (4) decreased
negative feedback signaling through ANG II [20].
The transcription control of renin gene expression has
been studied extensively by many groups. Numerous
studies have elucidated various transcription factors,
among which CREB is the best characterized. CREB reg-
ulates renin gene transcription by binding to speciﬁc and
non-speciﬁc (cis and trans) regulatory elements in the
50 UTR and 30 UTR of the renin gene [21–23]. However, as
the main second messenger for renin secretion is increase
in cAMP [24], all mechanisms increasing cAMP may
stimulate renin release, including prostaglandins E2 and I2
[25, 26], adrenomedullin [27], dopamine [28], and the
neurohormones CGRP [29] and PACAP [30]. Interestingly,
cytosolic calcium attenuates renin release. Since calcium
usually facilitates exocytosis, its inhibitory effect on renin
secretion has been coined as the ‘‘calcium paradox of renin
release’’ [31]. Recent data suggest that this effect is med-
iated through the reduction of cytosolic cAMP by calcium
[32, 33]. Calcium-mobilizing hormones such as ANG II,
endothelins, or vasopressin may thus inhibit the secretion
of renin [34–36].
Other mechanisms regulating renin release are under
investigation. We recently reviewed the important role of
nuclear hormone receptors in renin regulation [37]. Epi-
demiological studies show an inverse relationship between
vitamin D and plasma renin activity, suggesting an inhib-
itory effect of vitamin D on renin secretion [38]. One of the
mechanisms put forward is that the effect of vitamin on
renin secretion is mediated through an increase in intra-
cellular calcium [39]. Other experimental studies show that
the vitamin D receptor (VDR) binds retinoid X receptor
forming a heterodimer that competes with other regulators
for elements in the renin promoter. By this, it suppresses
renin transcription [37, 40–43]. In mice with total disrup-
tion of the gene encoding for the VDR, renal renin mRNA
levels are threefold higher than in wild-type mice, and
plasma ANG II is increased 2.5-fold. As the angiotensin-
ogen levels show no difference between both groups, the
increase in ANG II is attributed to increased renin activa-
tion [40].
In contrast to the extensive literature on transcriptional
regulation of renin, there is almost no knowledge on
genetic regulation of renin. Newton-Cheh et al. [44]
showed that aldosterone-to-renin ratio is heritable and that
modest linkage to chromosome 11p exists, but was not
associated with 17 common variants in the renin gene. We
are currently conducting genome-wide association studies
(GWAS) to link genetic variants to renin levels.
Finally, it is important to notice that most drugs used to
treat CV and renal disease can inﬂuence renin levels
(Table 1). ACEi and ARB, for example, are used to block
the RAAS; however, by doing so, they also block the ANG
II-negative feedback and therefore cause an increase in
renin levels. A rise in renin is also observed after admin-
istration of diuretics, mainly due to reduced circulatory
volume and neurohormonal feedback. In addition loop
diuretics can stimulate renin release by the inhibition of
macula densa sodium transport in the kidney, which
mimics a situation of low sodium delivery to the macula
densa and thus elicits renin secretion [45]. In contrast, beta-
blockers reduce renin levels through suppression of beta-
adrenergic stimulation of the kidney [46]. It is important to
dissect these effects from the physiological response, when
measuring RAAS activation.
The prorenin/renin receptor or (P)RR
The general assumption that prorenin is merely an inactive
precursor of renin has been challenged by the recent dis-
covery of the (pro-) renin receptor ((P)RR). This receptor
has been localized in various tissues, like brain, kidney, and
heart, speciﬁcally in vascular smooth muscle cells in human
heart and kidney, in glomerular mesangial cells and in distal
and collecting tubular cells in the kidney. (P)RR binds both
renin and prorenin [6]. Upon binding of prorenin to (P)RR,
the prosegment covering the active site of prorenin becomes
unfolded, and the enzymatic cleft exposed, activating pro-
renin in a non-proteolytic way [14] (Fig. 1). In addition
upon binding to the (P)RR, the enzymatic activity of renin is
increased [47] This renders the receptor an important reg-
ulator of tissue RAAS activity [17].
Interestingly, there is also evidence that the (P)RR may
exert (angiotensin independent) effects by the activation of
an intracellular postreceptor cascade. The cascade includes
the activation of mitogen-activated protein kinase
(MAPK), ERK1, ERK2, and phosphorylation of heat shock
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123protein 27 (HSP27), leading to enhanced synthesis of
DNA, plasminogen activator inhibitor-1 (PAI-1), collagen-
1, ﬁbronectin, and transforming growth factor-b1 (TGFb1)
[48–50]. This suggests an important role for (P)RR in the
tissue remodeling process and provides a mechanism
through which enzymatically inactive prorenin may exert
an effect. It is of note however that in the absence of a
speciﬁc inhibitor, we currently lack data whether (P)RR is
pathophysiologically relevant and a potential target for
treatment.
Plasma renin concentration versus activity
Although measurement of renin has long been used to
assess RAAS activation, prorenin levels may be of interest
as well. In addition to absolute renin and prorenin levels,
the prorenin/renin ratio may provide useful information to
dissect various pathways stimulating the RAAS and
potentially guide therapy.
Traditionally, renin levels have been estimated by
measuring its enzymatic activity. Plasma renin activity
(PRA) is expressed as the amount of angiotensinogen that
is converted to ANG I per time unit. This method is,
however, also dependent on the amount of angiotensino-
gen. Other methods are measurement of active renin con-
centration (ARC or APRC) with an antibody directed
against the active site of renin. These techniques show a
high correlation and measure both renin and activated
prorenin, but not inactive prorenin. Some authors also refer
to ARC using the term plasma renin concentration. It is,
however, important to make the distinction with total
plasma renin concentration (TPRC), which includes inac-
tive prorenin [51] The amount of prorenin is usually
determined as the difference between TPRC and ARC or
PRA, but can also be measured directly [52]. The distinc-
tion between PRA/ARC and TPRC has become even more
important with the discovery of the (P)RR and the devel-
opment of direct renin inhibitors that can block the active
site of renin. The distinction between PRA and ARC is less
clear, but may be of importance when angiotensinogen
levels are the rate-limiting factor and in evaluating the
effects of the (P)RR on renin activity. In an observational
study in heart failure patients, ARC appeared to be a better
predictor than PRA [53], underscoring the importance to
select the appropriate measuring technique for the popu-
lation of interest.
Evidence for a pivotal role of renin in heart
and/or renal failure
Although the RAAS ﬁrst has been described decades ago,
multiple new pathways and mechanisms are continuously
being discovered (Fig. 2). Renin plays a central role in all
of these pathways. By blocking the action or reducing the
plasma levels of ANG II, renin and prorenin production is
increased leading to accumulation of the upstream and
parallel RAAS components, including ANG I, ANG 1–7,
and ANG IV.
Several publications have shown a link between renin
levels and cardiovascular and/or renal disease [54, 55]. It
was assumed that renin acts through the activation of the
classical circulating and local RAAS systems and by
default could not exert direct effects or effects outside the
main cascade. Discovery of the (P)RR and various angio-
tensin subforms has challenged this view, and there is
increasing evidence that renin plays an important role in
the development of CV and renal disease independent of
the classical RAAS. Both observational and interventional
studies have sought to dissect the effect of renin from the
classical RAAS.
Prognostic value of plasma renin activity/concentration
Several studies have been published examining the asso-
ciation of renin with cardiovascular disease. In interpreting
these results, it is important to consider the background
medication, since these have a strong inﬂuence on renin
levels and can obscure the results, but also the technique
used to measure renin differs in the various studies. The
ﬁrst major prospective study on the association between
renin and the incidence of cardiovascular disease has been
Table 1 RAAS modulation by medication
PRC PRA ANG I ANG II PAC AT1R AT2R
ACEi ??? - -± ±
ARB ??? ? -- ?
DRI ?-- - -± ±
B Block --- - -± ±
Vit D ? - ? -± ? ±±
ACEi angiotensin-converting enzyme inhibitors, ARB angiotensin receptor blocker, DRI direct renin inhibitor, B Block beta-blocker, PRC plasma
renin concentration, PRA plasma renin activity, ANG I angiotensin I, ANG II angiotensin II, PAC plasma aldosterone concentration, AT1R
angiotensin type 1 receptor, AT2R angiotensin type 2 receptor, Vit D vitamin D
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123conducted by Alderman et al. in 1991. They measured PRA
and sodium excretion in 1,717 patients with an untreated
systolic blood pressure C160 mmHg or diastolic blood
pressure C95 mmHg or on antihypertensive medication.
Patients had not taken their antihypertensive drugs 4 weeks
prior to the PRA and sodium measurements. Comparison
of the high- versus low-renin group showed that high PRA
was associated with increased risk for incident myocardial
infarction even after adjustment for age, sex, race, cho-
lesterol, smoking, glucose, blood pressure, and use of beta-
blockers [54]. Several years later, Meade et al. conducted a
study in 803 untreated normotensive patients. In this
cohort, however, the relationship between renin (here:-
ARC) and CV events could not be conﬁrmed [56]. A recent
report from the Framingham Heart Study has shown an
association of renin (here: PRA) with short-term all-cause
mortality \3 years, but not long-term mortality or CV
disease (myocardial infarction, unstable angina pectoris,
stroke, or congestive heart failure). [55] The relationship
may have been obscured, however, by the use of various
antihypertensive drugs, including ACEi, diuretics, and
beta-blockers. Another study described patients with cor-
onary artery disease and reported that high renin
(PRA[2,30 ng/ml/h) was associated with cardiac mor-
bidity and mortality [57]. In interpreting these epidemio-
logical data, ANG II was generally thought to be the main
culprit [58]; however, in heart failure patients, high PRA
was also associated with mortality in both patients on ACEi
or ARB [4, 53]. Part of the observed associations may be
explained by ANG II and aldosterone breakthrough [59,
60], but it is important notice that other mechanisms may
play a role, such as direct effects of renin through the
(P)RR.
This distinction is crucial in the development of new
treatment for CV disease. Although the classical RAAS
may (temporarily) be blocked by ACEi, ARB, and ARAs
and has been shown to improve prognosis, the subsequent
rise of renin levels is worrisome, considering it is associ-
ated with adverse prognosis. Unfortunately, the afore-
mentioned studies by their observational design cannot
answer the question whether renin is a risk factor or indi-
cator reﬂecting neurohormonal activation due to compro-
mised circulation. Hopefully, interventional studies with
direct renin inhibitors and renin receptor blockers will
provide the answer.
Renin in cardiorenal interaction
Heart failure (HF) is often complicated by decreased renal
blood ﬂow and a subsequent decrease in glomerular ﬁl-
tration rate (GFR) [61, 62]. Decreased renal function is one
of the strongest predictors of mortality in patients with
advanced HF [61] In these patients, RAAS is not only
activated to maintain systemic circulatory volume, but
Fig. 2 Renin angiotensin system extended, (P)RR (pro-) renin
receptor, MAPK mitogen-activated protein kinase, ERK extracellu-
lar-signal-regulated kinase, HSP heat shock protein, ANG
angiotensin, AT1R/AT2R/AT4R angiotensin receptor type 1/2/4,
BKR bradykinin receptor, ACE angiotesin converting enzyme, MME
neprilysin
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123mainly to maintain GFR [63]. Initiation of RAAS blockade
is therefore often associated with an initial decrease in
GFR. Long-term RAAS activation, however, negatively
inﬂuences renal function, among others through ﬂuid and
salt retention and subsequent increase in congestion [62]
This is supported by the bidirectional relationship that is
observed between renin levels and renal function. In
addition, ANG II exerts various potentially harmful effects
including proliferative and proﬁbrotic effects. Activation of
RAAS may therefore lead to a downward spiral, which can
potentially be stopped by RAAS blockade. The potential
beneﬁt of interfering in the RAAS is supported by the
observation in the Val-Heft trial that double RAAS
blockade in patients with heart failure is especially bene-
ﬁcial in patients with kidney disease [64]. PRA and APRC
often are increased in patients with HF and renal dys-
function [61, 65]. Caution has to be taken, however, to
extrapolate these results to all patients with kidney disease,
since the ONTARGET and VALIANT trial showed
harmful effects of double RAAS blockade in patients with
resp. atherosclerotic vascular disease and left ventricular
dysfunction directly after myocardial infarction [66, 67].
Here, some RAAS activation may well be a necessary
compensatory mechanism. Interesting to notice is that in
contrast to patients with an estimated GFR (eGFR)\
60 ml/min/1,73 m
2, patients with proteinuria had
decreased PRA levels.
The aforementioned trials however interfered down-
stream of ANG I and did not target renin activity or con-
centration, since heart failure and kidney disease are
associated with increased renin levels, especially in the
presence of ACEi or ARB. Targeting PRA may prove
especially effective in these patients. The role of RAAS in
cardiorenal interaction however is complex. According to
the primary injury, as well as the stage of disease, activa-
tion can be either compensatory or harmful. Therapies
targeting PRA or PRC may provide important additional
evidence.
The (pro-) renin receptor in cardiorenal disease
Evidence regarding the role of the (P)RR in CV and kidney
disease is slowly becoming available. Studies with trans-
genic animals have shown evidence that (P)RR might be
related to CV and renal diseases. Rats with a ubiquitous,
yet moderate overexpression of (P)RR develop proteinuria
and progressive nephropathy, despite normal blood pres-
sure, suggesting a direct pathological role of (P)RR in renal
damage [68]. Rat models with a strong overexpression of
human (P)RR in vascular smooth muscle cells showed a
progressive increase in systolic blood pressure and heart
rate at 4 months of age, although kidney function remained
normal [69].
Mice that lack the gene encoding the (P)RR are not
viable. Recently, mice were generated with cardiore-
stricted deletion of (P)RR; these mice died because of
cardiomyocyte cell death due to acidiﬁcation. This does
not come as a complete surprise as the (P)RR not only
binds renin and prorenin, but also exerts other functions,
notably acting as a vacuolar ATPase and regulator of
cellular pH [70]. Furthermore, (P)RR also plays an
important role in neural development through renin-inde-
pendent mediation of wnt signaling [71] Pharmacological
inhibition of the (P)RR with a (P)RR-blocker could
therefore have provided conclusive evidence on the role of
the receptor in cardiac and renal disease. Development of
a drug blocking the activation of (P)RR by renin proved to
be very difﬁcult, since structure–function studies and
crystallographic data are lacking. Recently, a ‘handle
region peptide’ (HRP) has been discovered, which alleg-
edly blocks the (P)RR [72]. Several studies have sug-
gested that HRP may prevent and even reverse diabetic
nephropathy in diabetic rodents and diminish cardiac
ﬁbrosis in stroke-prone spontaneously hypertensive rats
[73, 74]. However, other studies have shown less prom-
ising results: HRP did not show any beneﬁcial effect in
high-renin low-prorenin Goldblatt rats [75] or mice
overexpressing prorenin [76]. The effectiveness of the
HRP in blocking the prorenin receptor is questioned, since
in vitro studies showed that prorenin binding to (P)RR
was not prevented by HRP [77]. In summary, although in
the future, the (P)RR may provide a novel opportunity to
treat CV and renal disease, and at this point, the exact
function of the (P)RR in CV and kidney disease remains
to be elucidated. In addition, caution has to be taken in
blocking (P)RR, since it appears to exerts renin-indepen-
dent effects beyond the cardiorenal system.
Renin blockade
As mentioned above, both ACEi and ARB increase renin
levels due to the loss of negative feedback of ANG II on
renin release. Despite the aforementioned clues that high
PRA might play a role in the progression of cardiac disease
in patients on RAAS blockade, conclusive evidence is
missing. Directly blocking the active site of renin may
provide important information. It was already in 1980 that
the ﬁrst studies were performed with a renin inhibitor [78];
however, the effectiveness of this renin inhibitor was poor,
mainly due to lack of speciﬁcity [79]. Recently, an orally
active renin inhibitor, aliskiren, has become commercially
available, and several other direct renin inhibitors are in
development. Numerous studies are now trying to establish
the potentials for this treatment in CV and renal disease.
Despite low bioavailability, aliskiren blocks the active site
of renin and effectively lowers PRA [80], thus providing
196 Heart Fail Rev (2012) 17:191–201
123very useful information on the role of PRA outside the
classical RAAS pathway.
Since aliskiren blocks PRA, it acts upstream of ACEi,
ARB of ARA and is believed to block the RAAS more
completely. Its exact effects on ANG 1–7, ANG 1–9, ANG
1–5, ANG III, and ANG IV formation, however, have not
been studied in detail. Aliskiren blocks the active site of
renin and can thus block both renin and non-proteolitically
activated prorenin. Therefore, it has the potential to block
both circulating and tissue RAAS. This has been supported
by the observation that aliskiren blocks tissue RAAS more
effectively that ACEi and ARB [81].
These assumptions have been supported by the obser-
vation that 3 months of aliskiren 150 mg once daily pro-
vided additional blood pressure lowering on top op of an
ACEi, ARB, or diuretic [82], and it reduced PRA, urinary
aldosterone, and BNP on top of ‘optimal’ therapy in stable
HF patients in the ALOFT trial [83]. Furthermore, aliskiren
reduced LV mass as much as Losartan, and the combina-
tion reduced LV mass slightly more, however not statisti-
cally signiﬁcant in patients with hypertension and left
ventricular hypertrophy [84]. Unfortunately, the ASPIRE
study did not show any improvement in echocardiographic
measurements in patients with left ventricular dysfunction
after myocardial infarction when treated with aliskiren on
top of beta-blockers and ACEi or ARB [85], neither did the
ALOFT trial in stable HF patients. This may however be
due to the short follow-up time.
Blocking PRA results in an increase in PRC. In diabetic
TG(mRen-2)27 rats, aliskiren did not prevent renin binding
of (pro-) renin to the (P)RR nor did it block the intracellular
cascades, and therefore, the intracellular cascades may
even increase due to higher PRC. Although an aliskiren-
induced suppression of gene expression of (P)RR was
observed in vivo, this was not observed in human mesan-
gial cells in vitro. The most likely explanation is that in
vivo high-(pro) renin levels inhibit (P)RR expression via
negative feedback [86]. The exact mechanism, however,
remains to be elucidated, and whether the increased PRC
results in harmful effects is still subject of debate [87].
Several studies are now on the way evaluating the
effects of aliskiren in patients with both systolic and dia-
stolic heart failure. The Atmosphere [88] is currently
investigating the effects of aliskiren compared to and on
top of Enalapril on morbidity and mortality in patients with
systolic heart failure, and the ASTRONAUT study is
investigating the effect of aliskiren in the acute HF setting
[89]. Studies on patients with diastolic heart failure are on
their way as well. The evidence for a potential effect of
renin blockade in diastolic heart failure is, however, scarce.
Patients with diastolic heart failure tend to have a higher
PRA than healthy controls, although not as high as patients
with systolic HF [90]; however, this may be due to
concomitant medication. Moreover, ACEi and ARB have
proven little beneﬁt in these patients so far [91–93]. The
effects of direct renin inhibition remain to be investigated.
There is also some evidence that direct renin inhibition
may improve renal function in patients with heart failure by
improving effective renal plasma ﬂow (ERPF). In a nor-
motensive population, direct renin inhibition has been
shown to have stronger beneﬁcial effects on renal hemo-
dynamics in comparison with ACEi [94]. There was also an
increase in ERPF observed in patients with diabetes type I
treated with direct renin inhibitors [95]. Whether these
results can be achieved in patients with heart failure and
decreased renal function is currently under investiga-
tion in the ARIANA-CHF-RD trial (clinicaltrials.gov id
NCT00881439). As mentioned above, the reactive rise of
PRC in patients on direct renin inhibition raises some
concern. Its effects, however, are unknown, since medi-
cation speciﬁcally lowering TPRC is missing.
There are a few agents that in addition to other effects
lower renin. First, beta-blockers have been proven beneﬁ-
cial in treatment of the entire spectrum of CV disease. Part
of their beneﬁcial effect is attributed to the decrease in
TPRC and PRA as a consequence of inhibition of the
beta1-adrenergic receptors in the JG cells [96]. Indeed,
several post hoc analyses of beta-blocker trials in patients
with heart failure showed that the beta-blockers lower
PRA [97].
Another therapy aimed to lower PRA and/or TPRC is
activation of the VDR. Several experimental studies show
that the selective vitamin D receptor activator paricalcitol
effectively reduces renin transcript levels and PRA in mice
[40, 98]. Furthermore, in Dahlt-salt sensitive rats [99] and
in Spontaneously Hypertensive Rats (SHR) [100], pari-
calcitol treatment attenuated the development of hyper-
tensive cardiomyopathy, which was ascribed at least in part
due to lower renin levels. In rat model of nephropathy,
paricalcitol lowered proteinuria associated with the inhi-
bition of the RAAS [101]. These promising experimental
results have been backed-up by small-scale clinical
observations. In small-scale clinical studies, administration
of 1,25(OH)2D3 showed reductions in PRA, ANG II lev-
els, BP, and myocardial hypertrophy [41, 102]. Kong et al.
also showed in a human pilot study in chronic hemodialysis
patients that treatment with VDR activators lowered PRA
in human subjects. The recently published VITAL study
[103] conﬁrmed the antiproteinuric effects of paricalcitol in
patients with CKD stage 3 and 4. The authors did not
observe changes in aldosterone and PRA, but stated that the
trial was not designed to measure effects on the RAAS.
Currently, the ‘‘Study to Investigate the Effects of Vitamin
D Administration on Plasma Renin Activity in Patients
With Stable Chronic Heart Failure (Vit D-CHF)’’ trial
investigates the effect of high-dose vitamin D on plasma
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123renin activity in chronic heart failure patients (clinicaltri-
als.gov id: NCT01092130).
Finally, more experimental approaches like gene ther-
apy with antisense oligos directed against renin are tested
for their value to reduce renin levels [104].
Future perspectives
Development of ACEi, and later ARBs, has substantially
improved the prognosis of patients with heart failure and/or
kidney disease. Morbidity and mortality, however, remain
high. Renin levels are generally elevated in these patients
because of chronic activation of the RAAS and compen-
satory increases in response to chronic use of RAAS
inhibitors. There is ample evidence that this might be
harmful. The development of renin inhibitors increases our
arsenal to modulate the RAAS and might provide evidence
as to whether increased renin activity is a cause for auto-
nomic progression of CV and kidney disease or merely a
risk indicator.
The development of new RAAS blockers also renews
the question whether RAAS-guided therapy may prove
additional beneﬁt. There has been a vigorous debate whe-
ther drug choice for the treatment of hypertension should
be based on PRA. Although currently PRA-based treatment
has not made it to the guidelines, the development of new
drugs however also provides us with new tools to block the
RAAS at different sites and promote better understanding
of the RAAS and alternative pathways.
The discovery of the (P)RR has also raised the question
as to effects of increased renin levels under renin blockade
and the potential of blocking the receptor itself. There have
been reports that a (P)RR-blocker has been developed, and
it may be a effective treatment in CV and renal disease
[73, 74]. However, these results have not be conﬁrmed by
other study groups, and more research is needed to fully
understand the role of (P)RR in CV disease.
Questions also arise about the role of prorenin in cardiac
and renal disease. The ALTITUDE-trial is currently
investigating the effect of a direct renin inhibitor in patients
with diabetes that usually have excessive levels of prorenin
[105] It is believed that prorenin may inﬂuence prognosis
by activating tissue RAAS, which can potentially be
blocked by direct renin inhibitors, but it may also exert a
direct effect through the (pro-) renin receptor. Results of
this trial may provide useful information for future
investigations.
In conclusion, the RAAS is an important regulatory
mechanism in heart failure and kidney disease. The system,
however, is not static and blockade of one of the compo-
nents results in upregulation of other pathways. Important
questions to be answered are which pathways are
deleterious and which may provide beneﬁcial effect in
different patient populations. Renin plays a pivotal role in
the activation of the RAAS and many of the alternative
pathways and will most likely become an important new
target for the treatment of CV and renal disease. Results of
ongoing trials with direct renin inhibitors as well as new
studies examining the different effects of renin concentra-
tion and activity will hopefully provide conclusive evi-
dence on the role of renin in cardiorenal disease.
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